Allon Therapeutics Wins National Biotech Award
BIOTECanada said Allon was chosen as the top pre-commercialization company in the Canadian biotechnology healthcare sector “by distinguishing themselves from their peers with demonstrated technology innovation and achieved milestones.”
Gordon McCauley, Allon’s President and CEO, said the prestigious Gold Leaf Award recognizes the Company’s clinical trial successes and progress toward commercializing products in devastating degenerative brain diseases, such as Alzheimer’s, Parkinson’s and several types of frontotemporal dementia.
“Being chosen as Canada’s leading pre-commercial healthcare biotech company is a great honour and an enormous compliment to the dedication, innovation, and excellence demonstrated by our team every day,” said McCauley. “It is also important recognition of the investigators, patients, and caregivers we partner with to find solutions to these awful diseases.”
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.